Jacobs Levy Equity Management Inc. Acquires 12,654 Shares of Inogen, Inc. (NASDAQ:INGN)

Jacobs Levy Equity Management Inc. boosted its holdings in Inogen, Inc. (NASDAQ:INGN) by 4.4% during the 4th quarter, Holdings Channel.com reports. The fund owned 303,522 shares of the medical technology company’s stock after purchasing an additional 12,654 shares during the quarter. Jacobs Levy Equity Management Inc.’s holdings in Inogen were worth $2,783,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD increased its holdings in Inogen by 5.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 26,710 shares of the medical technology company’s stock worth $245,000 after purchasing an additional 1,318 shares in the last quarter. Invesco Ltd. boosted its position in shares of Inogen by 2.0% during the fourth quarter. Invesco Ltd. now owns 78,142 shares of the medical technology company’s stock valued at $717,000 after buying an additional 1,545 shares during the last quarter. Wells Fargo & Company MN grew its holdings in Inogen by 27.8% during the fourth quarter. Wells Fargo & Company MN now owns 13,917 shares of the medical technology company’s stock worth $128,000 after buying an additional 3,031 shares in the last quarter. Bank of America Corp DE raised its position in Inogen by 2.7% in the 4th quarter. Bank of America Corp DE now owns 127,326 shares of the medical technology company’s stock valued at $1,168,000 after buying an additional 3,304 shares during the last quarter. Finally, AlphaQuest LLC bought a new position in Inogen during the 4th quarter valued at $43,000. Institutional investors own 89.94% of the company’s stock.

Inogen Trading Down 2.2%

INGN stock opened at $5.75 on Friday. The stock has a market cap of $154.60 million, a P/E ratio of -2.56 and a beta of 1.63. The stock’s fifty day simple moving average is $7.02 and its two-hundred day simple moving average is $8.82. Inogen, Inc. has a 1-year low of $5.70 and a 1-year high of $13.33.

Inogen (NASDAQ:INGN) last posted its quarterly earnings results on Wednesday, May 7th. The medical technology company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.27. The company had revenue of $82.28 million during the quarter, compared to analyst estimates of $79.57 million. Inogen had a negative net margin of 15.89% and a negative return on equity of 27.38%. As a group, analysts forecast that Inogen, Inc. will post -1.73 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently issued reports on INGN shares. Stifel Nicolaus reduced their target price on shares of Inogen from $10.00 to $7.00 and set a “hold” rating for the company in a research note on Thursday, May 8th. StockNews.com downgraded shares of Inogen from a “buy” rating to a “hold” rating in a research report on Wednesday, February 26th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Inogen in a research report on Wednesday, April 9th.

Inogen Company Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.